| Epiregulin: roles in normal physiology and cancer DJ Riese II, RL Cullum Seminars in cell & developmental biology 28, 49-56, 2014 | 178 | 2014 |
| The yin and yang of ERBB4: tumor suppressor and oncoprotein LM Lucas, V Dwivedi, JI Senfeld, RL Cullum, CP Mill, JT Piazza, IN Bryant, ... Pharmacological Reviews 74 (1), 18-47, 2022 | 36 | 2022 |
| Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics RL Cullum, LM Lucas, JI Senfeld, JT Piazza, LT Neel, K Whig, L Zhai, ... Plos one 15 (12), e0243901, 2020 | 4 | 2020 |
| ERBB4 Drives the Proliferation of BRAF-WT Melanoma Cell Lines LM Lucas, RL Cullum, JN Woggerman, V Dwivedi, JA Markham, ... medRxiv, 2022.06. 20.22276663, 2022 | 1 | 2022 |
| ERBB4Mutant Alleles Found inBRAFWT Melanomas That Drive the Proliferation of aBRAFWT Melanoma Cell Line LM Lucas, RL Cullum, JN Woggerman, V Dwivedi, JA Markham, ... | | 2022 |
| ERBB4 Mutant Alleles May Drive BRAF WT Melanomas LM Lucas, RL Cullum, JA Markham, JN Woggerman, V Dwivedi, ... medRxiv, 2022.06. 21.22276707, 2022 | | 2022 |
| The Simulated Random Assignment of Missense Mutations Throughout a Gene of Interest Can Determine Whether Missense Mutations Found in That Gene in a Population of Tumor Genomes … R Cullum, D Riese | | 2021 |
| Discovery and characterization of selective and nonselective inhibitors of ErbB4 signaling: Putative targeted melanoma therapeutics. LM Lucas, RL Cullum, JI Senfeld, LJ Cook, MH Harris, DZ Kaufmann, ... CANCER RESEARCH 80 (19), 40-41, 2020 | | 2020 |
| Identification of putative melanoma driver mutations in the ErbB4 receptor tyrosine kinase gene. RL Cullum, TM Ghosh, LM Lucas, D Waits, KM Halanych, DJ Riese CANCER RESEARCH 80 (19), 41-42, 2020 | | 2020 |
| Targeting BRAF WT metastatic melanomas: Identifying ERBB4 mutant alleles as biomarkers for novel combinatorial treatment strategies L Lucas, R Cullum, V Dwivedi, D Waits, T Ghosh, D Kaufmann, E Knerr, ... European Journal of Cancer 138, S32, 2020 | | 2020 |
| Abstract A21: Identification of putative melanoma driver mutations in the ErbB4 receptor tyrosine kinase gene RL Cullum, TM Ghosh, LM Lucas, D Waits, KM Halanych, DJ Riese Cancer Research 80 (19_Supplement), A21-A21, 2020 | | 2020 |
| Abstract A19: Discovery and characterization of selective and nonselective inhibitors of ErbB4 signaling: Putative targeted melanoma therapeutics LM Lucas, RL Cullum, JI Senfeld, LJ Cook, MH Harris, DZ Kaufmann, ... Cancer Research 80 (19_Supplement), A19-A19, 2020 | | 2020 |
| Targeting BRAF WT metastatic melanomas: Identifying ERBB4 mutations as biomarkers for novel combinatorial treatment strategies L Lucas, R Cullum, D Waits, T Ghosh, L Cook, D Kaufmann, J Markham, ... Cancer Research 80 (16_Supplement), 5932-5932, 2020 | | 2020 |
| Melanoma drug discovery: Prioritization of candidate melanoma driver mutations in the ErbB4 receptor tyrosine kinase gene and identification of novel molecules that disrupt … RL Cullum Auburn University, 2020 | | 2020 |
| Mutations in ERBB4 may account for clinical resistance of melanomas to inhibitors of the RAS/RAF/MEK/MAPK pathway RL Cullum, T Ghosh, L Lucas, D Waits, D Riese Cancer Research 79 (13_Supplement), 2144-2144, 2019 | | 2019 |
| Abstract A159: Characterization of putative ErbB4 antagonists: targeted melanoma drug discovery RL Cullum, LM Lucas, JT Piazza, JI Senfeld, LT Neel, RB Gupta, ... Molecular Cancer Therapeutics 17 (1_Supplement), A159-A159, 2018 | | 2018 |
| Screening methodologies for the discovery of small molecule melanoma therapeutics targeted at the ErbB4 receptor tyrosine kinase RL Cullum, JT Piazza, JI Senfeld, LT Neel, RB Gupta, AE David, DJ Riese Cancer Research 77 (13_Supplement), 1245-1245, 2017 | | 2017 |
| Validation and implementation of screens for partial agonists and antagonists of the ErbB4/HER4 receptor tyrosine kinase: Targeted melanona drug discovery R Cullum, A David, DJ Riese Cancer Research 76 (14_Supplement), 1353-1353, 2016 | | 2016 |
| A high-throughput screening process for the discovery of melanoma chemotherapeutics targeted at the ErbB4 receptor tyrosine kinase RL Cullum, RB Gupta, DJ Riese CANCER RESEARCH 75, 2015 | | 2015 |
| Abstract B17: A high-throughput screening process for the discovery of melanoma chemotherapeutics targeted at the ErbB4 receptor tyrosine kinase RL Cullum, RB Gupta, DJ Riese Cancer Research 75 (14_Supplement), B17-B17, 2015 | | 2015 |
